Bank of New York Mellon
SONN

Bank of New York Mellon’s Sonnet BioTherapeutics SONN Stock Holding History

Bank of New York Mellon’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8
Closed -$46K – 4464
2021
Q1 		$46K Buy
+8
New +$50.6K ﹤0.01% 4274
2017
Q2 		– Hold
0
– -$7K – 4339
2017
Q1 		– Hold
0
– – – 4263
2016
Q4 		– Hold
0
– – – 4251

Other funds holding SONN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MSFS
Main Street Financial Solutions Newtown, Pennsylvania $1.56B AUM 24.84% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon's SONN Position: Q2 2021 in Review

Bank of New York Mellon sold out of Sonnet BioTherapeutics (SONN) in Q2 2021, closing a stake of 8 shares — an estimated $46K sold.

Bank of New York Mellon first reported a position in SONN in Q1 2021 and held it in 1 quarter. The position peaked at $46K in Q1 2021. 9 funds tracked by Wall St. Rank hold SONN as of Q2 2021.

  • Bank of New York Mellon reported no remaining Sonnet BioTherapeutics position as of Q2 2021 after selling out during the quarter.
  • Bank of New York Mellon sold 8 Sonnet BioTherapeutics shares in Q2 2021, an estimated $46K.
  • Bank of New York Mellon first reported a position in Sonnet BioTherapeutics in Q1 2021 and held it in 1 quarter.
  • Bank of New York Mellon's Sonnet BioTherapeutics position peaked at $46K in Q1 2021.
  • 9 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q2 2021.

Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.